1. Home
  2. NUVB vs TECX Comparison

NUVB vs TECX Comparison

Compare NUVB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$9.41

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$21.73

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVB
TECX
Founded
2018
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
359.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NUVB
TECX
Price
$9.41
$21.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$10.63
$81.20
AVG Volume (30 Days)
6.1M
328.8K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,748,000.00
N/A
Revenue This Year
$609.55
N/A
Revenue Next Year
$197.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1137.19
N/A
52 Week Low
$1.54
$13.70
52 Week High
$9.75
$61.07

Technical Indicators

Market Signals
Indicator
NUVB
TECX
Relative Strength Index (RSI) 72.70 61.57
Support Level $9.06 $17.79
Resistance Level $9.75 $19.12
Average True Range (ATR) 0.50 1.24
MACD 0.00 0.17
Stochastic Oscillator 88.21 95.25

Price Performance

Historical Comparison
NUVB
TECX

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: